These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16758643)

  • 1. State of central and peripheral pools of hemopoietic precursor cells in patients with malignant neoplasms during chemotherapy.
    Khrichkova TY; Gol'dberg VE; Matyash MG; Vysotskaya VV
    Bull Exp Biol Med; 2005 Nov; 140(5):635-9. PubMed ID: 16758643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responses of Blood System to Doxorubicin/Docetaxel Chemotherapy in Patients with Breast Cancer.
    Goldberg VE; Polyakova TY; Popova NO; Vysotskaya VV; Simolina EI; Dudnikova EA; Goncharova NM; Belevich YV; Grigor'ev EG; Goldberg AV; Dygai AM
    Bull Exp Biol Med; 2019 Dec; 168(2):275-279. PubMed ID: 31782001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cytostatics on bone marrow stem cells.
    Goldberg ED; Dygai AM; Zhdanov VV
    Bull Exp Biol Med; 2005 Jan; 139(1):121-5. PubMed ID: 16142293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of Granulocytopoiesis Recovery Stimulation with Filgrastim in Breast Cancer Patients Receiving Chemotherapy.
    Goldberg VE; Polyakova TY; Popova NO; Vysotskaya VV; Simolina EI; Dudnikova EA; Goncharova NM; Belevich YV; Tuzikova TP; Goldberg AV; Miroshnichenko LA; Udut EV; Simanina EV; Zyuz'kov GN; Zhdanov VV; Dygai AM
    Bull Exp Biol Med; 2018 Nov; 166(1):63-68. PubMed ID: 30450524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early suppressive effects of chemotherapy on recovery of bone marrow megakaryocyte precursors: possible relationship to platelet recovery.
    Warren MK; Zujewski J; Rose WL; Szabo JM; O'Shaughnessy JA; Halverson DC; Cowan KH; Gress RE; Schwartz GN
    Stem Cells; 1996; 14 Suppl 1():31-7. PubMed ID: 11012200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compensatory reactions during impairment of granulocytic stem in patients with lung cancer receiving antitumor chemotherapy.
    Gol'dberg VE; Zhdanov VV; Matyash MG; Simolina EI; Khrichkova TY; Vysotskaya VV; Popova NO; Boldyshev DA
    Bull Exp Biol Med; 2001 Jun; 131(6):564-7. PubMed ID: 11586408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group.
    Narabayashi M; Takeyama K; Fukutomi T; Tokuda Y; Tajima T; Okumura A; Chou T; Sano M; Makino H; Igarashi T; Sasaki Y; Imoto S; Ogura M; Morishima Y; Murai H; Okamoto S; Ikeda T; Kasai M; Yokozawa T; Tobinai K
    Jpn J Clin Oncol; 1999 Jun; 29(6):285-90. PubMed ID: 10418556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
    Kasimir-Bauer S; Mayer S; Bojko P; Borquez D; Neumann R; Seeber S
    Clin Cancer Res; 2001 Jun; 7(6):1582-9. PubMed ID: 11410494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drug counters doxorubicin cardiotoxicity; not for use at start of chemotherapy.
    Am J Health Syst Pharm; 1995 Oct; 52(19):2076. PubMed ID: 8535936
    [No Abstract]   [Full Text] [Related]  

  • 10. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-chemotherapy and cytokine pretreated marrow stromal cell layers suppress hematopoiesis from normal donor CD34+ cells.
    Schwartz GN; Warren MK; Rothwell SW; Zujewski J; Halverson DC; Cowan KH; Tolcher A; O'Shaughnessy J; Gress RE
    Bone Marrow Transplant; 1998 Sep; 22(5):457-68. PubMed ID: 9733269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem cell defects after cytoreductive therapy in man.
    Schreml W; Lohrmann HP; Anger B
    Exp Hematol; 1985; 13 Suppl 16():31-42. PubMed ID: 2985415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Start tamoxifen after completing chemotherapy, US researchers say.
    McCarthy M
    Lancet; 2002 Jun; 359(9321):1925. PubMed ID: 12057564
    [No Abstract]   [Full Text] [Related]  

  • 14. Hemopoietic precursors: mechanisms of regulation under conditions of chronic stress.
    Sherstoboev EY; Minakova MY
    Bull Exp Biol Med; 2005 Nov; 140(5):616-20. PubMed ID: 16758639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms of hemopoiesis cytostatic damage and regeneration].
    Gol'dberg ED; Dygaĭ AM; Zdanov VV
    Vestn Ross Akad Med Nauk; 1998; (10):6-10. PubMed ID: 9846103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
    Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Nagasawa S
    Cancer; 1994 Mar; 73(6):1678-85. PubMed ID: 7512436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for adjuvant chemotherapy.
    Schabel FM
    Cancer; 1977 Jun; 39(6 Suppl):2875-82. PubMed ID: 141322
    [No Abstract]   [Full Text] [Related]  

  • 18. Does outcome of breast cancer depend on dose and dose intensity of adjuvant chemotherapy?
    Mittra I
    Natl Med J India; 1994; 7(5):221-2. PubMed ID: 7827602
    [No Abstract]   [Full Text] [Related]  

  • 19. Muehrcke's lines on nails after cyclophosphamide/adriamycin/fluorouracil.
    Gül U; Kiliç A
    Ann Pharmacother; 2004 Jun; 38(6):1089-90. PubMed ID: 15122002
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial.
    ; Ambrosini G; Balli M; Garusi G; Demicheli R; Jirillo A; Bonciarelli G; Bruscagnin G; Fila G; Bumma C; Lacroix F; Buzzi F; Di Costanzo F; Padalino D; Brugia M; Calabresi F; Natali M; Cartei G; Chiesa G; Blasina B; Ciambellotti E; Moro G; D'Aquino S; Altavilla G; Adamo V; De Maria D; Falchi AM; Bertoncelli P; Farris A; Fiorentino M; Fornasiero A; Fosser V; Daniele O; Foggi CM; Speranza GB; Sartori S; Camilluzzi E; Gallo L; Poggio R; Secondo V; Gambi A; Grignani F; Capodicasa E; Lopez M; Papaldo P; Di Lauro L; Vici P; Marenco G; Folco U; Bonanni F; Marsilio P; Palazzotto G; Di Carlo A; Cusimano MP; Pastorino G; Puccetti C; Giusto M; Rausa L; Gebbia N; Palmeri S; D'Alessandro N; Saccani F; Becchi G; Schieppati G; Spinelli I; Tagliagambe A; Tonato M; Minotti V; Ardia A; Viaro D; De Micheli P; Zingali G; Sacchetti G; Intini C
    J Clin Oncol; 1988 Jun; 6(6):976-82. PubMed ID: 2897433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.